6 completed, 3 not yet recruiting, 3 recruiting, 2 withdrawn. 14 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 6, Not yet recruiting 3, Recruiting 3, Withdrawn 2 |
| Phase 1 | 3 | Completed 2, Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Normal saline placebo: new trials by email Literature Review of Normal saline placebo trials Research Report on Normal saline placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Local Iloprost Therapy to Promote Bone Healing in High Risk Fractures Ilomedin, Normal saline placebo - Nonunion Bone Fracture, Fractures Ununited | Phase 2 | Not yet recruiting | Charite University, Berlin, Germany | 60 | 2027-01-01 | 2026-11-09 |
| Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo - Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 30 | 2026-11-01 | 2026-09-02 |
| Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy Cerebrolysin, Normal saline placebo - Acute Ischemic Stroke | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 100 | 2026-09-01 | 2026-08-11 |
| Intravesical Aminophylline to Facilitate Ureteroscopic Access in Children With Distal Ureteral Stones. Aminophylline, Normal Saline Placebo - Pediatric Urolithiasis, Distal Ureteral Stone | Phase 2 | Recruiting | Beni-Suef University | 60 | 2026-05-09 | 2026-06-01 |
| Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients Umbilical Cord Mesenchymal Stem Cells, Normal saline placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Recruiting | RSUP Persahabatan | 20 | 2025-08-08 | 2026-02-27 |
| A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV - Influenza, Human, SARS-CoV-2 Infection | Phase 2 | Completed | Pfizer | 644 | 2024-01-31 | 2025-09-30 |
| A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV). Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF - Healthy Participants | Phase 2 | Completed | Pfizer | 1142 | 2023-06-05 | 2024-12-18 |
| Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults QBKPN SSI, Normal Saline Placebo - Immune Deficiency | Phase 2 | Recruiting | Qu Biologics Inc. | 72 | 2023-04-11 | 2025-01-22 |
| A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP Recombinant Human Plasma Gelsolin, Normal Saline Placebo - Community-acquired Pneumonia | Phase 1 / Phase 2 | Completed | BioAegis Therapeutics Inc. | 33 | 2018-08-28 | 2020-01-27 |
| Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever HTNV/PUUV DNA vaccine, Placebo, TriGrid Delivery System (TDS) - Hemorrhagic Fever With Renal Syndrome | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 130 | 2014-07-09 | 2021-02-12 |
| Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension Albuterol., Normal saline placebo - Idiopathic Pulmonary Arterial Hypertension. | Phase 2 | Withdrawn | American Medical Association Foundation | 2014-06-01 | 2015-12-30 | |
| A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. Belimumab, Normal saline placebo - Purpura, Thrombocytopaenic, Idiopathic | Phase 2 | Withdrawn | GlaxoSmithKline | 2013-03-01 | 2014-07-28 | |
| Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis Intravenous Magnesium Sulfate, Normal Saline Placebo - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Medical College of Wisconsin | 208 | 2010-12-01 | 2016-01-27 |
| Immunomodulatory Properties of Ketamine in Sepsis Ketamine, Normal Saline placebo - Sepsis | Phase 1 / Phase 2 | Completed | Beth Israel Deaconess Medical Center | 19 | 2009-12-01 | 2017-08-21 |
COVID-19 (2) · Influenza, Human (2) · Anemia, Sickle Cell (1) · Community-Acquired Pneumonia (1) · Familial Primary Pulmonary Hypertension (1) · Fractures, Bone (1) · Fractures, Ununited (1) · Hemorrhagic Fever with Renal Syndrome (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Ischemic Stroke (1) · Prostatic Neoplasms (1) · Pulmonary Disease, Chronic Obstructive (1) · Purpura (1) · Sepsis (1)
Pfizer (2) · American Medical Association Foundation (1) · Beni-Suef University (1) · Beth Israel Deaconess Medical Center (1) · BioAegis Therapeutics Inc. (1) · Chang Gung Memorial Hospital (1) · Charite University, Berlin, Germany (1) · GlaxoSmithKline (1) · Medical College of Wisconsin (1) · Qu Biologics Inc. (1) · RSUP Persahabatan (1) · The Methodist Hospital Research Institute (1) · U.S. Army Medical Research and Development Command (1)
United States (7) · Australia (1) · Canada (1) · Egypt (1) · Georgia (1) · Indonesia (1)
Brian Miles, MD (1) · Daniel Talmor, MD, MPH (1) · David Brousseau, MD, MS (1) · Hany F Badawy, MD (1) · Kristopher Paolino, MD (1) · Marcel Niemann, PD Dr. med. (1) · Mark J DiNubile, MD (1) · Matthew Lammi, MD (1) · Theodore Steiner, MD FRCPC (1)
PMID 24443249, PMID 26232172, PMID 28606098, PMID 32690640, PMID 40006705